RecruitingPhase 2NCT07625293

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

A Phase 2a Study of DB-3Q for the Treatment of Medically Refractory Crohn's Disease

Sponsor

Direct Biologics, LLC

Enrollment

36 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Crohn Disease (CD)

Summary

This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called DB-3Q and Placebo for people with crohn disease (cd). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.